Autumn Newsletter

Over the Easter and ANZAC period the team at the clinic will be taking a little break. The clinic with be closed from 19th to 25th April inclusive.

Current patients with urgent medical related queries are advised to contact their treating physician on the mobile number provided. Alternatively non- urgent medical enquiries can be addressed to nurse@mscc.com.au which will be monitored periodically.

Assoc. Professor Freitag will be away from 19th April and returning to consulting 29th April.

Recruitment has now ceased for our donor stem cell trial. We have completed the trial treatment phase and will have results of the safety of the treatment by May 2019. Treatment effectiveness will take longer and we expect those results early in 2020.

For anyone who doesn’t meet the criteria of our current trials but is interested in being involved in future trials that we are considering sign up now by clicking here. At MSCC we treat osteoarthritis, but that doesn’t stop calls relating to other conditions. For these calls we suggest having a look at the ANZCTR website to see what studies are currently open to patients within Australia and New Zealand.

Our latest trial for 2019 is currently in it’s recruitment phase. This is a small 10 participant trial assessing the safety and efficacy treating osteoarthritis in the small joints of the hand. For patients who have already had a Lipoharvest, we will be looking to commence this trial in the coming months. If you would like to express your interest in this trial please contact nurse@mscc.com.au

We have completed an overhaul of our research page on our website. Currently the doctors within the Melbourne stem cell centre team have many published articles on osteoarthritis conservative management on our website. Click here to view more.

As most patients will be aware we use custom build research survey software called clinical intelligence to attend to our growing list of research surveys for patients to complete after their treatment. After feedback from patients about the pros and cons of these surveys as well as comments from our clinical team we will be looking to assess and review software over the next 12 months. We will work closely with the software developers to streamline this process making it easier and quicker to complete these surveys.